Piramal Pharma Ltd (PPLPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Piramal Pharma Ltd on NSE and BSE, with an AI summary of each filing.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HDFC Mutual Fund
Acquisition/ Disposal of Shares · 31 Oct 2026, 4:48 pm
HDFC Mutual Fund Trims Stake in Piramal Pharma to 4.988% Schemes of HDFC Mutual Fund sold 2,69,92,907 equity shares, representing a 2.027% stake, in Piramal Pharma Limited via open market transactions on 28th Oct'26. Following this disposal, HDFC Mutual Fund’s aggregate shareholding in the company decreased from 7.015% (9,33,93,655 shares) to 4.988% (6,64,00,748 shares) of the total paid-up equity capital. The company's total equity share capital remains unchanged at Rs. 13,31,34,81,300, comprising 1,33,13,48,130 equity shares of Rs. 10 each.
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI LODR Regulations, 2015
Intimation · 30 Oct 2026, 9:47 pm
Piramal Pharma Schedules Institutional Investor Meetings in Mumbai Piramal Pharma announced its schedule for physical institutional investor meetings in Mumbai under SEBI LODR Regulations. The company will participate in group and one-on-one meetings arranged by Avendus Spark on 17th Nov'26, followed by meetings organized by JM Financial Services on 18th Nov'26. Both sessions are subject to scheduling changes based on exigencies from either party.
Please find enclosed details of Earning call Transcript held on 28th October 2026.
Transcript · 30 Oct 2026, 8:28 pm
Please find enclosed intimation of audio recordings of the conference call held today 28th October, 2026.
Audio / Video · 28 Oct 2026, 10:15 pm
Piramal Pharma Releases Q2 FY27 Earnings Conference Call Audio Recording Piramal Pharma Limited has made available the audio recording of its earnings conference call held on 28th Oct'26. The call discussed the company's standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with Regulation 30(6) of SEBI LODR Regulations, the recording has been uploaded to the company's official website for investor access.
Please find enclosed Investor presentation for quarter ended 30 September, 2026
Investor Presentation · 28 Oct 2026, 2:36 am
Piramal Pharma Delivers Strong Q2FY27 Results and Upgrades Full-Year Guidance Piramal Pharma reported consolidated Q2FY27 revenue of ₹2,617 Cr, up 28% YoY, led by CDMO (+36%) and CHG (+32%). EBITDA surged 72% YoY to ₹385 Cr, with margins expanding 372 bps YoY to 14.7% due to operational leverage and cost optimization. PAT turned positive to ₹5 Cr versus a ₹99 Cr loss in Q2FY26. H1FY27 revenue rose 23% YoY to ₹4,887 Cr. Management raised its FY27 revenue growth guidance to 19–20%, expecting meaningfully higher profitability as H2 is typically stronger.
Please find enclosed Press release for quarter ended 30 September, 2026
Press Release · 28 Oct 2026, 2:34 am
Piramal Pharma Reports Strong Q2FY27 Results and Upgrades Full-Year Guidance Piramal Pharma delivered strong Q2FY27 consolidated performance, with revenue from operations growing 28% YoY to ₹2,617 Cr and EBITDA surging 72% YoY to ₹385 Cr, expanding margins by 372 bps YoY to 14.7%. PAT turned positive at ₹5 Cr versus a ₹99 Cr loss in Q2FY26. Growth was led by CDMO (+36% YoY to ₹1,424 Cr) and CHG (+32% YoY to ₹849 Cr). Driven by robust H1 order inflows, the company upgraded its FY27 revenue growth guidance to 19%-20% with meaningfully higher profitability.
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 28 Oct 2026, 2:32 am
Please find enclosed unaudited financial results for Q2 FY 27
Financial Result · 28 Oct 2026, 2:29 am
Outcome of Board Meeting of Piramal Pharma Limited held on 27th October, 2026
Outcome · 28 Oct 2026, 2:23 am
Piramal Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,617 (+28.1% YoY | +15.3% QoQ) ■ EBITDA: 349 (+119.8% YoY | +78.7% QoQ) ■ EBITDA Margin (%): 13.3 (+556 bps YoY | +473 bps QoQ) ■ PAT: 5.6 (Loss to Profit YoY | Loss to Profit QoQ) ■ EPS (INR): 0.04 (Loss to Profit YoY | Loss to Profit QoQ)
Piramal Pharma Limited has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 27 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 27 Oct 2026, 5:30 am
Please find enclosed intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 ('SEBI Listing Regulations')
Intimation · 28 Oct 2026, 10:00 am
Piramal Pharma Schedules Q2 and H1 FY27 Earnings Call for 28th Oct'26 Piramal Pharma Limited will host an earnings conference call for investors and analysts on 28th Oct'26 from 10:00 AM to 10:45 AM IST to discuss financial results for Q2 and H1 FY27. Primary Indian dial-in numbers include +91 22 6280 1461 and +91 22 7115 8320, alongside international toll-free access for the US, UK, Singapore, and Hong Kong. DiamondPass registration is available to reduce wait times.
Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results ....
Intimation · 27 Oct 2026, 5:30 am
Piramal Pharma Board to Consider Q2 Results on 27th Oct'26 Piramal Pharma Limited announced that its Board of Directors will meet on 27th Oct'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, the trading window for dealing in company securities, which closed on 1st Oct'26, will remain shut until 29th Oct'26 (both days inclusive) in compliance with SEBI listing regulations.
Please refer attachment.
Others (Uncategorized) · 02 Oct 2026, 1:40 am
Piramal Pharma to Conclude Distribution Agreement with Bayer Pharmaceuticals Piramal Pharma announced that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals will conclude upon natural expiry on 31st Dec'26, with no renewal beyond the current term. The company earned commission-based income under this pact, which accounts for under 5% of its consolidated revenue. Given its commission-based structure, the non-renewal is not expected to have a material impact on Piramal Pharma's profitability or overall financial position, and the company is working with Bayer to ensure an orderly operational transition.
Please refer attachment.
Others (Uncategorized) · 02 Oct 2026, 12:33 am
Piramal Pharma Clarifies $1.7 Million Government Funding for Aurora Facility Piramal Pharma clarified that its Aurora facility received a $1.7M funding grant from the Government of Ontario under the Life Sciences Scale-Up Fund program to support infrastructure upgrades, modernization, and operational efficiency. The company stated that this funding is non-material under SEBI Regulation 30, with no expected material impact on financial performance or operations. Additionally, management confirmed that any recent movements in share price or trading volume are purely market-driven, with no undisclosed material information.
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 -Appointment of Senior Management Personnel.
Change in Management · 01 Oct 2026, 1:38 am
Piramal Pharma Appoints Viral Gandhi as Chief Technology Officer Piramal Pharma Limited’s Board of Directors approved the appointment of Mr. Viral Gandhi as Chief Technology Officer and Senior Management Personnel, effective 1st Oct'26. Mr. Gandhi currently serves as President and Group CIO at Piramal Group, bringing over 25 years of technology strategy experience. His prior roles include CIO at Cox & Kings Group and leading digital transformation engagements at Tata Consultancy Services (TCS) for Fortune 100 clients. Mr. Gandhi is not related to any Director of the company.
Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Changes in Senior Management Personnel.
Change in Management · 30 Sept 2026, 11:25 pm
Piramal Pharma Appoints Brian Guy as President and COO of Piramal Critical Care Piramal Pharma Limited announced the appointment of Brian Guy as President and COO of Piramal Critical Care, effective 19th Oct'26, following the retirement of Jeffrey Hampton on 27th Nov'26. Guy brings over 25 years of pharmaceutical industry experience in commercial operations and business leadership, having previously served as President and Chief Commercial Officer at Breckenridge Pharmaceutical, Inc. with full U.S. P&L responsibility since 2018. In his new role, Guy will focus on driving expansion within the company's Complex Hospital Generics portfolio.
The Exchange has sought Clarification from Piramal Pharma Ltd with reference to the media report appearing on https://www.thehindubusinessline.com/ dated September 30, 2026 (Link: https://www.thehindubusinessline.com/brandhub/pr-release/ontario-contributes-17-million-investment-to-advance-life-sciences-innovation-at-piramal-pharmas-aurora-facility/article71526588.ece) ....
Others (Uncategorized) · 30 Sept 2026, 11:23 pm
Please refer attachment.
Others (Uncategorized) · 29 Sept 2026, 4:29 pm
Piramal Pharma Receives GST Demand and Penalty Order Totaling ₹8.12 Crore Piramal Pharma received an Order-in-Original from CGST Mumbai East confirming an Input Tax Credit demand of Rs. 4.06 cr along with applicable interest and an equivalent penalty of Rs. 4.06 cr for FY'21 to FY'23. The tax dispute pertains to post-demerger transitional ITC, ISD registrations, and cross-charged expenses from Piramal Enterprises. The company intends to appeal the order before appellate authorities within prescribed timelines and expects no material impact on its financials or operations.
Please refer attached file
Others (Uncategorized) · 19 Sept 2026, 1:09 am
Piramal Pharma Receives 'Leader' ESG Rating of 67.1 from Niche99 Piramal Pharma Limited announced that Niche Ninety Nine Capability and Certifications (OPC) Private Limited (Niche99) has assigned the company an Environment, Social, and Governance (ESG) rating of 67.1, placing it in the 'Leader' band. The assessment was communicated via BSE on 17th Sep'26. The company clarified that it did not engage Niche99 for the rating, which was independently prepared using publicly available information.
Please refer attached file
Others (Uncategorized) · 15 Sept 2026, 1:20 am
Piramal Pharma Receives US FDA Form-483 with Seven Observations for Morpeth Facility The US FDA conducted a GMP inspection at Piramal Pharma’s Morpeth, UK facility from 3rd Sep'26 to 11th Sep'26, concluding with the issuance of Form-483 containing 7 observations. The observations relate to enhancements in operational practices, procedures, and documentation. Piramal Pharma stated it is actively addressing these points and preparing a detailed response for submission to the US FDA within the stipulated timeline, aiming to resolve all matters in close coordination with the regulator.
Please refer attached file
Intimation · 08 Sept 2026, 9:03 pm
Piramal Pharma Schedules UK Institutional Investor Meetings in Sep'26 Piramal Pharma Limited announced institutional investor meetings scheduled for 29th and 30th Sep'26 in the United Kingdom. The physical interactions, arranged by Avendus Spark Institutional Equities, will comprise group and one-on-one formats.
Please refer attached file
Others (Uncategorized) · 03 Sept 2026, 7:58 pm
Piramal Pharma Secures Improved NSE ESG Rating of 65 for FY26 On 3rd Sep'26, Piramal Pharma disclosed an upgraded ESG rating of 65 for FY26, assigned voluntarily by NSE Sustainability Ratings and Analytics. This reflects a marginal improvement from the previous score of 64. The rating was independently prepared using public domain data without formal engagement by the company. The slight upward revision highlights Piramal Pharma's incremental progress in sustainable and responsible corporate operations.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Deutsche Bank AG
Acquisition/ Disposal of Shares · 26 Aug 2026, 10:51 pm
Piramal Pharma Share Pledge Update Deutsche Bank AG, as security agent, disclosed a re-creation of a pledge over 98,400,000 shares (7.39% of total share capital) in Piramal Pharma by borrower CA Alchemy Investments on 24 Aug'26. This action follows a previous release of the same number of shares. After this transaction, the total shares pledged in favour of the security agent reverted to 238,663,700, representing 17.93% of Piramal Pharma's share capital. This encumbrance is for a facility agreement where Deutsche Bank acts as security agent for the lenders.
Please refer attached file
Others (Uncategorized) · 24 Aug 2026, 10:31 pm